BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman
LYNBROOK, N.Y., March 18, 2019 /PRNewswire/ -- BioSpecifics Technologies Corporation (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced with great sadness that Thomas L. Wegman, President of BioSpecifics, passed away on March 13, 2019. Mr. Wegman served as an officer at BioSpecifics for over 20 years and was a member of the Board of Directors since 1994.
"It is with great sadness that we report the passing of Tom Wegman. The entire BioSpecifics family mourns this loss and on behalf of our Board of Directors and employees, we send our condolences to the Wegman family," said Michael Schamroth, an Independent Director of the BioSpecifics Board of Directors. "BioSpecifics was founded by Tom's late father, Edwin H. Wegman, and Tom certainly fulfilled his legacy in his more than 20 years with the company. Tom brought BioSpecifics to new heights and we hope to continue in his legacy in this next chapter with the BioSpecifics team."
BioSpecifics will continue to be actively managed by its current employees and Board of Directors. Succession planning is underway and new management positions will be announced.
About BioSpecifics Technologies Corp.
View original content to download multimedia:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-announces-passing-of-president-thomas-l-wegman-300813630.html
SOURCE BioSpecifics Technologies Corp.
Company Codes: NASDAQ-NMS:BSTC